PURPOSE: To evaluate feasibility of an exercise intervention consisting of high-intensity interval endurance and strength training in breast cancer patients. METHODS:Twenty-six women with nonmetastatic breast cancer were consecutively assigned to the exercise intervention- (n= 15, mean age 51.9 ± 9.8 years) and the control group (n = 11, mean age 56.9 ± 7.0 years). Cardiopulmonary exercise testing that included lactate sampling, one-repetition maximum tests and a HADS-D questionnaire were used to monitor patients both before and after a supervised six weeks period of either combined high-intensity interval endurance and strength training (intervention group, twice a week) or leisure training (control group). RESULTS: Contrarily to the control group, endurance (mean change of VO2, peak 12.0 ± 13.0%) and strength performance (mean change of cumulative load 25.9 ± 11.2%) and quality of life increased in the intervention group. No training-related adverse events were observed. CONCLUSIONS: Our guided exercise intervention could be used effectively for initiation and improvement of performance capacity and quality of life in breast cancer patients in a relatively short time. This might be especially attractive during medical treatment. Long-term effects have to be evaluated in randomized controlled studies also with a longer follow-up. Implications for Rehabilitation High-intensity interval training allows improvement of aerobic capacity within a comparable short time. Standard leisure training in breast cancer patients is rather suitable for the maintenance of performance capacity and quality of life. Guided high-intensity interval training combined with strength training can be used effectively for the improvement of endurance and strength capacity and also quality of life. After exclusion of contraindications, guided adjuvant high-intensity interval training combined with strength training can be safely used in breast cancer patients.
RCT Entities:
PURPOSE: To evaluate feasibility of an exercise intervention consisting of high-intensity interval endurance and strength training in breast cancerpatients. METHODS: Twenty-six women with nonmetastatic breast cancer were consecutively assigned to the exercise intervention- (n= 15, mean age 51.9 ± 9.8 years) and the control group (n = 11, mean age 56.9 ± 7.0 years). Cardiopulmonary exercise testing that included lactate sampling, one-repetition maximum tests and a HADS-D questionnaire were used to monitor patients both before and after a supervised six weeks period of either combined high-intensity interval endurance and strength training (intervention group, twice a week) or leisure training (control group). RESULTS: Contrarily to the control group, endurance (mean change of VO2, peak 12.0 ± 13.0%) and strength performance (mean change of cumulative load 25.9 ± 11.2%) and quality of life increased in the intervention group. No training-related adverse events were observed. CONCLUSIONS: Our guided exercise intervention could be used effectively for initiation and improvement of performance capacity and quality of life in breast cancerpatients in a relatively short time. This might be especially attractive during medical treatment. Long-term effects have to be evaluated in randomized controlled studies also with a longer follow-up. Implications for Rehabilitation High-intensity interval training allows improvement of aerobic capacity within a comparable short time. Standard leisure training in breast cancerpatients is rather suitable for the maintenance of performance capacity and quality of life. Guided high-intensity interval training combined with strength training can be used effectively for the improvement of endurance and strength capacity and also quality of life. After exclusion of contraindications, guided adjuvant high-intensity interval training combined with strength training can be safely used in breast cancerpatients.
Entities:
Keywords:
Breast cancer; HIT; high-intensity interval training; secondary prevention; strength training
Authors: Pedro Lopez; Daniel A Galvão; Dennis R Taaffe; Robert U Newton; Giovani Souza; Gabriel S Trajano; Ronei S Pinto Journal: Breast Cancer Date: 2020-08-19 Impact factor: 4.239
Authors: Sara Mijwel; Malin Backman; Kate A Bolam; Anna Jervaeus; Carl Johan Sundberg; Sara Margolin; Maria Browall; Helene Rundqvist; Yvonne Wengström Journal: Breast Cancer Res Treat Date: 2017-11-14 Impact factor: 4.872
Authors: Mohammad Keilani; Franz Kainberger; Anna Pataraia; Timothy Hasenöhrl; Barbara Wagner; Stefano Palma; Fadime Cenik; Richard Crevenna Journal: Wien Klin Wochenschr Date: 2019-07-02 Impact factor: 1.704
Authors: Daniel A Bizjak; Sebastian V W Schulz; Uwe Schumann; Stephanie Otto; Johannes Kirsten; Florian Ebner; Elena Leinert; Jens Huober; Wolfgang Janni; Jürgen Michael Steinacker Journal: Cancers (Basel) Date: 2020-06-10 Impact factor: 6.639